JPRN-jRCT2021200029进行中（未招募）3 期
A0003 Eye Drops 0.55% Phase III Study in Cystinosis Patients
Ito Shuichi0 个研究点目标入组 14 人开始时间: 2020年12月7日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 14
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Considered by the investigator or the sub-investigator being eligible for study participation, based on the results of screening tests conducted within 8 weeks before administration of A0003 Eye Drops 0.55%
- •Whose leukocyte cystine concentration measured before initiation of Cysteamine treatment was > 1 nmol/1/2 cystine/mg protein or who was diagnosed with cystinosis
- •Cystine crystal deposits in whose cornea was detected by slit lamp examination conducted at screening tests
- •Has ability to or intend to comply with the 4 times daily instillation regimen
排除标准
- •Patients who have used Cysteamine eye drops within 1 year before administration of A0003 Eye Drops 0.55%
- •Patients with uncontrolled hepatic disorder, cardiovascular disease, neurologic disease, or a cancer complication
- •Patients with a history of hypersensitivity to Cysteamine, benzalkonium chloride, disodium edetate, carmellose sodium, citric acid monohydrate, or penicillamine
研究者
相似试验
已完成
3 期
Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye DiseaseDry Eye SyndromesNCT02229955Hanlim Pharm. Co., Ltd.86
进行中（未招募）
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EGFR-Amplified Newly diagnosed glioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003171-64-DEAbbVie Deutschland GmbH & Co.KG90
进行中（未招募）
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EUCTR2017-003171-64-NLAbbVie Deutschland GmbH & Co.KG40
进行中（未招募）
1 期
Study for the Management of Ocular Side Effects in Participants with Epidermal Growth Factor Receptor (EGFR)-amplified GlioblastomaReceiving Depatuxizumab Mafodotin (ABT-414)EGFR-Amplified Newly diagnosed glioblastomaMedDRA version: 20.0Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-003171-64-GBAbbVie Deutschland GmbH & Co.KG90
已完成
3 期
A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye DiseaseDry Eye DiseaseNCT06544694Alcon Research79